Travere Therapeutics, Inc.
TVTX
株式のランク
#3489
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
株価
$52.43
時価総額
$4.94B
変化（1日）
3.83%
変化（1年）
87.97%
国
US
取引 Travere Therapeutics, Inc. (TVTX)
カテゴリー
Healthcare
Travere Therapeutics, Inc.（TVTX）の株式分割履歴
Travere Therapeutics, Inc.株（シンボル：TVTX）は合計で2回の株式分割を実施しました。
最新の株式分割はNov 02, 2012に行われました。
Jul 02, 2009より前に購入されたTVTX株は、現在0.0011111111111111TVTX株に相当します。
最新の株式分割はNov 02, 2012に行われました。
Jul 02, 2009より前に購入されたTVTX株は、現在0.0011111111111111TVTX株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 2012-11-02 | 1:9 | x0.11111111111111 | x0.0011111111111111 |
| 2009-07-02 | 1:100 | x0.01 | x0.01 |
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
